Panbela Therapeutics Inc
NASDAQ:PBLA
Panbela Therapeutics Inc
NASDAQ:PBLA
Price:
0.3811 USD
0.03%
Updated:
May 8, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of PBLA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PBLA
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
PBLA Competitors Multiples
Panbela Therapeutics Inc Competitors
Panbela Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Panbela Therapeutics Inc
NASDAQ:PBLA
|
1.8m USD | 0 | -0.1 | -0.1 | -0.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
282.8B USD | 5.2 | 58.7 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
163.1B USD | 5.5 | 43.4 | 18.4 | 30.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.8B USD | 11 | 30 | 24.2 | 25.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.5B USD | 8.1 | 27.3 | 22.1 | 24.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81B USD | 3 | 167.4 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.5B USD | 9 | -7.8 | -8.5 | -7.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.3 | 27.5 | 14.1 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.3 | 46 | 63.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
